Egetis Therapeutics Q4: Approved in EU, launch in Germany in Q2 - Redeye
Redeye returns with an updated view of Egetis Therapeutics following the Q4 report and the recent approval in the EU. 2025 looks like an interesting year -with a launch in EU and a likely US filing.
ANNONS
Redeye returns with an updated view of Egetis Therapeutics following the Q4 report and the recent approval in the EU. 2025 looks like an interesting year -with a launch in EU and a likely US filing.